Radionuclide therapy in oncology.
Clarke
S E
SE
Department of Nuclear Medicine, Guys Hospital, London.
D019797:3-Iodobenzylguanidine; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000532:radiotherapy / Q000556:secondary; D001918:Brachytherapy; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use; D007462:Iodobenzenes / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy*; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D011868:Radioisotopes / Q000627:therapeutic use*; D011879:Radiotherapy Dosage; D012211:Rhenium / Q000627:therapeutic use; D012493:Samarium / Q000627:therapeutic use; D013326:Strontium Radioisotopes / Q000627:therapeutic use; D013964:Thyroid Neoplasms / Q000532:radiotherapy
D000911:Antibodies, Monoclonal; D007457:Iodine Radioisotopes; D007462:Iodobenzenes; D010761:Phosphorus Radioisotopes; D011868:Radioisotopes; D013326:Strontium Radioisotopes; D019797:3-Iodobenzylguanidine; D012493:Samarium; D012211:Rhenium